Levish-M Tablet is a combination medication containing Levocetirizine 5mg and Montelukast 10mg, formulated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine is a potent, selective antagonist of peripheral histamine H1-receptors, providing effective relief from symptoms like sneezing, nasal congestion, itching, and rhinorrhea by inhibiting the action of histamine released during allergic reactions. Montelukast, a leukotriene receptor antagonist, blocks the cysteinyl leukotriene receptor, thereby reducing inflammation, bronchoconstriction, and mucus production associated with asthma and allergic rhinitis. The synergistic action of these two agents offers comprehensive control of allergic symptoms by targeting multiple pathways involved in the allergic response. Levish-M is indicated for patients requiring both antihistaminic and anti-inflammatory effects to improve symptom control and quality of life. It is generally well-tolerated, with a favorable safety profile; common adverse effects may include headache, fatigue, and gastrointestinal discomfort. Levish-M should be used under medical supervision, with dosage adjustments based on clinical response and patient tolerance. It is contraindicated in individuals with known hypersensitivity to its components. This combination therapy provides an effective option for managing allergic disorders requiring dual pharmacological intervention.